On Capitol Hill, there has been a flurry of activity on legislation related to expanding access to medication for opioid use disorder treatment, extending the classification of illicit fentanyl analogues as Schedule I under the Controlled Substances Act (CSA), and removing barriers to financial services for cannabis-related businesses. As the 117th Congress continues, below is…
We have witnessed first-hand the devastation that the opioid epidemic has wrought on states in terms of lives lost and the costs it has imposed on our healthcare system and the broader economy.
Washington, D.C. — The National Association of Attorneys General (NAAG) sent a letter asking the U.S. Food and Drug Administration (FDA) to examine recent progress in the agency’s fight against the opioid epidemic. The bipartisan coalition of state and territory attorneys general is seeking a progress report regarding recent steps taken by the FDA to…
Attorneys General Urge Congress to Repeal Ensuring Patient Access and Effective Drug Enforcement Act of 2016
The Act, which was signed into law on April 19, 2016, is a step backward in our collective effort to prevent the diversion and misuse of prescription drugs and address our worsening epidemic of opioid addiction and overdose deaths.
States and localities are on the front line of this crisis and are a large part of winning the battle from both a law enforcement and public health perspective.
This legislation is crucial to federal and state efforts to curb the opioid epidemic nationally and within each individual state. It is for these reasons that we commend Senators Portman and Manchin for their leadership in bringing forward this important legislation, and we urge you to take up and pass S. 2701 before the DEA’s temporary order expires.
State attorneys general have been fighting the opioid crisis on numerous fronts, including protecting consumers from deceptive marketing of prescription opioids, disrupting illicit trafficking networks, and closing pill mills.
The Road to Recovery Act will remove an unnecessary restriction on Medicaid funding for in-patient drug treatment. The restriction is a holdover from the original 1965 Medicaid law that was intended to discourage the use of inhumane and ineffective state-run asylums. The bill will remove this restriction for drug treatment while appropriately keeping it in place for mental health institutions. This change has been called for by providers, the medical establishment, governors of both parties and the President’s Commission on Combating Drug Addiction and the Opioid Crisis because it will make treatment affordable for those who need it, and create market incentives for new treatment resources. The bill also contains a provision to make it easier for children to access drug treatment.
Unfortunately, there are three significant barriers to treating opioid use disorder that we cannot change at the state level and that must be tackled at the federal level. We share these barriers below in the hope that we can work together to remove them and allow more providers to offer treatment for opioid use disorder and other substance use disorders.
The Draft Report should be revised to clearly state that there is no completely safe opioid dose, and that higher doses are particularly – and predictably – risks.